{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:23:54Z","timestamp":1794025434986,"version":"4.8.0"},"reference-count":11,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,11,1]]},"DOI":"10.2169\/internalmedicine.6867-25","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:08:49Z","timestamp":1773698929000},"page":"2835-2839","source":"Crossref","is-referenced-by-count":1,"title":["Enhancer of Zeste Homolog 1 and 2 Inhibitor-induced Colitis Mimicking Immune Checkpoint Inhibitor-induced Colitis"],"prefix":"10.2169","volume":"65","author":[{"given":"Keisuke","family":"Iwata","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Gifu Prefectural General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu Prefectural General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Kushima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shiga University of Medical Science, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gifu Prefectural General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hayase","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gifu Prefectural General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu Prefectural General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritaka","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu Prefectural General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu Prefectural General Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Zinzani PL, Izutsu K, Mehta-Shah N, et al. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (Valentine-PTCL01): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 25: 1602-1613, 2024.","DOI":"10.1016\/S1470-2045(24)00503-5"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Izutsu K, Makita S, Nosaka K, et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma. Blood 141: 1159-1168, 2023.","DOI":"10.1182\/blood.2022016862"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Maruyama D, Jacobsen E, Porcu P, et al. Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study. Lancet Oncol 25: 1589-1601, 2024.","DOI":"10.1016\/S1470-2045(24)00502-3"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology 160: 1384-1393, 2021.","DOI":"10.1053\/j.gastro.2020.08.063"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Collins M, Soularue E, Marthey L, Carbonnel F. Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review. Clin Gastroenterol Hepatol 18: 1393-1403.e1, 2020.","DOI":"10.1016\/j.cgh.2020.01.033"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yanai S, Toya Y, Sugai T, Matsumoto T. Gastrointestinal adverse events induced by immune-checkpoint inhibitors. Digestion 102: 965-973, 2021.","DOI":"10.1159\/000518543"},{"key":"7","unstructured":"7. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). version 5.0. U.S. Dept of Health and Human Services, 2017 [Internet]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Huang J, Zhang J, Guo Z, et al. Easy or not-the advances of EZH2 in regulating T cell development, differentiation, and activation in antitumor immunity. Front Immunol 12: 741302, 2021.","DOI":"10.3389\/fimmu.2021.741302"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Stairiker CJ, Thomas GD, Salek-Ardakani S. EZH2 as a regulator of CD8+ T cell fate and function. Front Immunol 11: 593203, 2020.","DOI":"10.3389\/fimmu.2020.593203"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Porazzi P, Nason S, Yang Z, et al. EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell 43: 537-551.e7, 2025.","DOI":"10.1016\/j.ccell.2025.01.013"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Huang H, Deng X, Yu L, et al. EZH1\/2 alteration as a potential biomarker for immune checkpoint inhibitors across multiple cancer types. J Transl Med 21: 913, 2023.","DOI":"10.1186\/s12967-023-04759-3"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/21\/65_6867-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:33:30Z","timestamp":1794022410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/21\/65_6867-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,1]]},"references-count":11,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6867-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,11,1]]},"article-number":"6867-25"}}